Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 11Multiple Myeloma 7Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Ovarian Neoplasms 2Neurofibrosarcoma 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Congenital Abnormalities 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1

Interventions

selinexor 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Doxorubicin 2ribociclib 1pembrolizumab 1pegfilgrastim 1metarrestin 1ixazomib 1fludarabine phosphate 1fludarabine 1cixutumumab 1X-Rays 1Specimen Handling 1Radiation 1Photons 1Nivolumab 1Mesna 1Ifosfamide 1High-Energy Shock Waves 1Filgrastim 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neurofibrosarcoma × selinexor × Clear all
NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

University Health Network, Toronto

Phase 1 Completed
56 enrolled
GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Columbia University

Phase 1 Withdrawn
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡